Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger maintains a Buy rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and raises the price target from $16 to $18.
May 15, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger maintains a Buy rating on Arcutis Biotherapeutics and raises the price target from $16 to $18.
The Buy rating and increased price target from a reputable analyst are likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100